**Business Performance:** Consolidated revenue for FY26 was up 12.3% YoY to 1,875 Cr.

Domestic sales jumped 19.6%, and international revenue grew 9.3%, with standalone Q4 hitting a new record.

Renal care and 'Others' segments showed strong growth. **Growth Strategy:** Acquisitions like Citieffe (Orthopaedics) and PendraCare (Cardiology) are expanding market & tech.

The company plans to double R&D spend, launching new products yearly, and building two new Indian plants for Medtech localization & cost optimization. **Recent Highlights:** FY26 saw 35 new product launches, over 11,000 stent deployments, and initial sales of Drug Eluting Balloons (DEB). Dialysis machine installed base reached ~1000. Management focuses on high-growth segments and boosting 'Made in India' products. **Financial Snapshot:** Consolidated Operating EBITDA was 458 Cr (24.4% margin), PAT 321 Cr.

Standalone Operating EBITDA hit 26.8%, meeting guidance.

Liquidity is strong at 842.2 Cr, with Return on Invested Capital (ROIC) firm at 21.2%.